Applications of Fmoc-(R)-3-Amino-4-(2,4-Dichloro-Phenyl)-Butyric Acid in Industrial Manufacturing

Fmoc-(R)-3-Amino-4-(2,4-Dichloro-Phenyl)-Butyric Acid is a high-purity raw material integral to the synthesis of specialty peptides, pharmaceutical intermediates, custom APIs, and advanced biomedical research compounds. As the direct manufacturer, we ensure consistent product quality and batch-to-batch reliability to meet the stringent standards required by regulated industries worldwide.

1. Chiral Peptide Synthesis for Clinical Research

This material supports the solid-phase synthesis of chiral peptides containing dichlorinated aromatic amino acid residues. Researchers use it to access precise stereochemistry critical for preclinical and investigational drug peptides. Its Fmoc protection ensures high purity and minimal racemization during automated peptide assembly, with compatibility across various coupling and cleavage protocols.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP General Chapter <795> and <797> (Aseptic compounding)
• EDQM (European Directorate for the Quality of Medicines) guidelines for peptide substances
• ISO 9001:2015 Quality Management Systems

Typical usage ratio

• One equivalent per peptide elongation cycle, molar ratio 1:1 with the growing peptide chain, adjustable for sequence complexity and scale

Downstream process integration

• Charged into peptide synthesizer during each Fmoc-protected residue coupling step after deprotection; ensures position-specific incorporation for sequence-verified products

Final product types

• Chiral peptide reference standards
• Research-grade oligopeptides
• Preclinical candidate peptides
• Specialty peptide reagents for SAR studies

2. Pharmaceutical Intermediate for Small Molecule APIs

In the development of new chemical entities containing substituted butyric structures, this raw material serves as a chiral intermediate for regulated API synthesis. Its dichlorophenyl moiety introduces required hydrophobic character and metabolic stability to target molecules. Pharmaceutical plants integrate it at early or mid-synthesis stages via reliable amidation, acylation, or coupling processes under strict process controls.

Industry compliance standards

• 21 CFR Part 211—Current Good Manufacturing Practice for Finished Pharmaceuticals (US FDA)
• EU GMP Part II—Basic Requirements for Active Substances used as Starting Materials
• Ph. Eur. monograph 2034 (Amino acid derivatives)
• APIC Guidance on ICH Q7 Implementation

Typical usage ratio

• Varies from 1 to 3 equivalents depending on synthetic stage and required yield; stoichiometry often optimized in pilot batches

Downstream process integration

• Added as a building block during chiral center installation or side-chain elaboration; reacts with activated esters, acid chlorides, or carbodiimide reagents under anhydrous conditions

Final product types

• Chiral pharmaceutical intermediates
• Key fragments for advanced API synthesis
• Protected drug substance intermediates
• Regulated active compounds with butyric acid side chains

3. Custom Peptide API Manufacturing

Contract manufacturers for peptide APIs rely on this chiral Fmoc-amino acid derivative to ensure sequence identity and purity in GMP-compliant production. It features high compatibility with both batch and continuous solid-phase synthesis workflows, supporting high-throughput peptide assembly lines. Well-documented impurity profiles and trace metal specs support submission-ready API process validation.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• US FDA Guidance for Industry: Peptide Drug Substances
• WHO GMP for Pharmaceutical Products
• ISO 13485 (for cGMP-grade synthesis requiring device-related peptides)

Typical usage ratio

• Typically 0.95–1.05 equivalents relative to resin-bound amine during each coupling stage; ratio optimized to avoid resin overloading and minimize waste

Downstream process integration

• Incorporated at sequence-specific coupling steps on automated peptide synthesizers or larger-scale batch reactors, followed by Fmoc deprotection and chain extension, under nitrogen atmosphere

Final product types

• Regulatory-compliant peptide APIs
• Peptide-based drug substances for clinical trials
• Bioactive peptide ingredients for advanced therapeutics
• Custom NCE peptide products under CDMO contracts

4. Analytical Standards and Reference Substances

High-purity batches are supplied as certified analytical standards and reference substances for pharmaceutical QA/QC laboratories. Regulatory bodies and manufacturers use these standards for HPLC assay calibration, mass spectrometry verification, and chiral purity quantification of related substances in regulated environments. Batch traceability and full documentation accompany each shipment for audit readiness.

Industry compliance standards

• USP Reference Standards Program
• Ph. Eur. General Notices for Reference Substances
• ISO/IEC 17025 Laboratory Accreditation (relevant for test labs)
• ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances

Typical usage ratio

• Standard preparation at 1–10 mg per laboratory test, weight adjusted for instrument sensitivity and calibration method; not used on production scale

Downstream process integration

• Directly dissolved into analytical grade solvent for calibration runs or spiked into genuine process streams during method validation, as required by regulatory protocols

Final product types

• Certified reference standards for chiral amino acid analysis
• System suitability test solutions for HPLC/UPLC
• Calibration standards for regulatory submissions
• Chiral marker substances for in-process permeation tests

5. Building Block in High-Specificity Diagnostic Probes

Biomedical technology firms utilize this protected amino acid to synthesize peptide-based molecular probes with dichlorophenyl groups that enhance receptor binding specificity. The compound is integrated into solid-phase or solution-stage synthesis of diagnostic peptides, which are then conjugated to labels for imaging or assay purposes in clinical and life science laboratories. Documentation supports compliance in regulated IVD or RUO use.

Industry compliance standards

• ISO 13485:2016 Quality Management for Medical Devices
• US FDA 21 CFR Part 820 (Quality System Regulation for Medical Devices)
• CE-IVD Directive 98/79/EC (for EU diagnostic reagents)
• ISO 15189:2012 Medical Laboratories—Requirements for Quality and Competence

Typical usage ratio

• One molar equivalent incorporated per labeled diagnostic peptide, with scale based on target assay batch size and molecular probe design

Downstream process integration

• Assembled onto solid-phase peptide chains, then released and conjugated to fluorophores, enzymes, or other detection markers

Final product types

• Fluorescently labeled peptide diagnostic reagents
• Targeted affinity probes for biomarker quantification
• Customized peptide-based imaging agents
• RUO and IVD peptide probe formulations